JAMA Cardiology

05/26/2026

Burst exercise testing detected more severe ventricular arrhythmias and prompted treatment escalation more often than the Bruce protocol in patients with , with no observed safety concerns.

This cohort study evaluates the diagnostic yield and therapeutic impact of the Burst exercise stress testing protocol compared with the traditional Bruce protocol in catecholaminergic polymorphic ventricular tachycardia.

05/25/2026

RBM20 truncating variants were associated with reduced lifetime penetrance and milder disease in compared to pathogenic RBM20 or titin variants, suggesting a low-effect role in arrhythmogenic cardiomyopathy.

https://ja.ma/4dZZu18

05/25/2026

Among men with localized , treatment with GnRH agonist leuprolide resulted in greater 12-month coronary plaque progression vs GnRH antagonist relugolix, driven by increased noncalcified plaque volume. https://ja.ma/4nK8Ykm

05/24/2026

Premature menopause (age

05/23/2026

In patients with and , conduction system pacing ( ) was inferior to biventricular pacing ( ) for a composite of death, heart failure events, and LVEF change at 12 months.

https://ja.ma/3PmSodP

05/23/2026

In the open-label extension of the ATTRibute-CM randomized clinical trial, early and continuous treatment with acoramidis in patients with transthyretin amyloid cardiomyopathy ( ) resulted in durable reductions in all-cause and cardiovascular mortality, as well as first cardiovascular hospitalization, through 54 months.

Continuous acoramidis stabilized NT-proBNP and functional outcomes (6-minute walk distance and Kansas City Cardiomyopathy Questionnaire), while biomarker improvements and clinical stability were also observed in patients switched from placebo to acoramidis. No new long-term safety concerns were identified.

https://ja.ma/4tVDFEB

05/22/2026

RBM20 truncating variants were associated with reduced lifetime penetrance and milder disease in compared to pathogenic RBM20 or titin variants, suggesting a low-effect role in arrhythmogenic cardiomyopathy. https://ja.ma/4a0M42s

05/21/2026

Editor's Note: Oral therapies offer new options for cardiovascular risk reduction, supporting shared decision-making for patients and clinicians as the landscape evolves beyond injectable agents.

Over the past 2 decades, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the therapeutic landscape for cardiovascular, kidney, and metabolic (CKM) care.1 Since the approval of the first GLP-1 RA (exenatide) in 2005 by the US Food and Drug Administration (FDA), randomized...

05/20/2026

Hospital adoption of the Resuscitation Quality Improvement program was not associated with improved survival to discharge or return of spontaneous circulation for in-hospital cardiac arrest.

https://ja.ma/4eSx5LA

05/19/2026

A prespecified secondary analysis of FINEARTS-HF evaluated the EMPEROR-Preserved risk model for predicting outcomes in adults with heart failure with mildly reduced or preserved ejection fraction ( or ).

The biomarker-driven model, incorporating N-terminal pro-B-type natriuretic peptide, high-sensitivity cardiac troponin T, New York Heart Association class, and comorbidities, showed good discrimination and calibration for a composite outcome of heart failure hospitalization or cardiovascular death, as well as for cardiovascular and all-cause death.

The relative treatment effect of finerenone was consistent across risk categories, but absolute benefits were greater in higher-risk patients.

https://ja.ma/4uONF3A

05/18/2026

In a US cohort, higher systolic genetic risk was associated with new-onset after pregnancy, but elevated postpartum body mass index and hypertensive disorders of pregnancy were stronger risk factors. https://ja.ma/4ukaRa5